Recent advances in mantle cell lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop (Q30456436)

21 June 2017

1 reference

title

Recent advances in mantle cell lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop (English)

1 reference

21 June 2017

0 references

1 reference

Leo I Gordon

6

0 references

author name string

Michael E Williams

1

1 reference

21 June 2017

Steven H Bernstein

2

1 reference

21 June 2017

Pedro Jares

3

1 reference

21 June 2017

Brad S Kahl

4

1 reference

21 June 2017

Thomas E Witzig

5

1 reference

21 June 2017

language of work or name

1 reference

4 March 2013

1 reference

21 June 2017

1 reference

21 June 2017

54

1 reference

21 June 2017

9

1 reference

21 June 2017

1882-1890

1 reference

Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma.

21 June 2017

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

Widespread microRNA repression by Myc contributes to tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

SOX11 expression correlates to promoter methylation and regulates tumor growth in hematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

Epigenetic activation of SOX11 in lymphoid neoplasms by histone modifications.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: growth inhibition by receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

Transcriptional role of cyclin D1 in development revealed by a genetic-proteomic screen.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

Interleukin 21: combination strategies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.771400

10.3109/10428194.2013.771400

21 January 2018

Identifiers

DOI

1 reference

21 June 2017

1 reference